Trial Profile
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumour patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2015
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- 28 Oct 2015 New trial record